Literature DB >> 9631750

Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus.

Y B Park1, S K Lee, D S Kim, J Lee, C H Lee, C H Song.   

Abstract

OBJECTIVE: To determine serum interleukin-10 (IL-10) levels in systemic lupus erythematosus (SLE) patients and to assess their relationship with disease activity.
METHODS: Forty-one SLE patients and 35 controls were studied. Paired serum samples were collected from all SLE patients at the time of their presentation with active disease and at 4 weeks after the institution of treatment. IL-10 levels were determined in the sera and were compared with disease activity, measured using the SLE Disease Activity Index (SLEDAI) and laboratory parameters such as the circulating immune complexes (CIC), C3, C4, anti-DNA antibody, IgG, IgM, and IgA.
RESULTS: The IL-10 levels in SLE patients were significantly higher than those of controls (mean +/- SE, 29.2 +/- 6.8 vs. 3.5 +/- 0.6 pg/ml, p < 0.01). Elevated IL-10 levels correlated well with the SLEDAI in SLE patients (r = 0.46, p < 0.01), but did not correlate with other laboratory activity indices. The changes in serum IL-10 levels also correlated with the changes in the SLEDAI score during the patients' disease course (r = 0.51, p < 0.01).
CONCLUSION: Serum levels of IL-10 are elevated in SLE patients and increased IL-10 correlates well with SLE disease activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9631750

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  66 in total

Review 1.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

2.  IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease.

Authors:  C Gasche; S Bakos; C Dejaco; W Tillinger; S Zakeri; W Reinisch
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

Review 3.  New therapies in development for autoimmune diseases: their rationale for combination treatment.

Authors:  V Strand
Journal:  Springer Semin Immunopathol       Date:  2001

4.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

5.  IVIg attenuates TLR-9 activation in B cells from SLE patients.

Authors:  Aharon Kessel; Regina Peri; Tharwat Haj; Ayelet Snir; Gleb Slobodin; Edmond Sabo; Itzhak Rosner; Yehuda Shoenfeld; Elias Toubi
Journal:  J Clin Immunol       Date:  2010-10-05       Impact factor: 8.317

6.  Interleukin-10 receptor expression and signalling were down-regulated in CD4⁺ T cells of lupus nephritis patients.

Authors:  H D Cui; Z M Qi; L L Yang; L Qi; N Zhang; X L Zhang; S Y Du; Y Jiang
Journal:  Clin Exp Immunol       Date:  2011-06-02       Impact factor: 4.330

7.  Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.

Authors:  Sander I van Leuven; Yanice V Mendez-Fernandez; Ashley J Wilhelm; Nekeithia S Wade; Curtis L Gabriel; John J Kastelein; Erik S Stroes; Paul P Tak; Amy S Major
Journal:  Ann Rheum Dis       Date:  2011-09-27       Impact factor: 19.103

8.  IL-21 mediates suppressive effects via its induction of IL-10.

Authors:  Rosanne Spolski; Hyoung-Pyo Kim; Wei Zhu; David E Levy; Warren J Leonard
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

9.  IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus.

Authors:  Christophe Richez; Kei Yasuda; Ramon G Bonegio; Amanda A Watkins; Tamar Aprahamian; Patricia Busto; Rocco J Richards; Chih Long Liu; Regina Cheung; Paul J Utz; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

Review 10.  Pathogenesis of systemic lupus erythematosus.

Authors:  C C Mok; C S Lau
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.